Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

0;Jun. 30, Jun. 30, 2013201220132012Revenue:  License and milestone revenue$ 50,000$
-$   50,000$
-  Collaboration services revenue4,6842,1237,5304,050Total revenue54,6842,12357,5304,050Operating expenses*:  Research and Development45,30015,38581,08431,213  Less: Excess amounts related to Research and Development(17,377)-(17,377)-Research and Development, net27,92315,38563,70731,213  General and Administrative17,7364,22037,7628,281  Less: Excess amounts related to General and Administrative(3,006)-(3,006)-General and Administrative, net14,7304,22034,7568,281Total operating expenses42,65319,60598,46339,494Income (loss) from operations12,031(17,482)(40,933)(35,444)Interest and other income (expense), net(23)4756103Income (loss) before income taxes12,008(17,435)(40,877)(35,341)Income tax benefit3435291,3175,612Net income (loss)$ 12,351$ (16,906)$ (39,560)$ (29,729)Net income (loss) per share:Basic$
.17$
(0.24)$
(0.55)$
(0.43)Diluted$
.16$
(0.24)$
(0.55)$
(0.43)Weighted average shares used to computenet income (loss) per share:Basic72,95369,08171,94868,965Diluted77,19469,08171,94868,965* Includes share-based compensation as follows:Research and development$
3,760$
,013$   14,940$
3,708General and administrative3,10183515,4991,625$
,861$
,848$   30,439$
5,333 

 Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)(unaudited; in thousands, except per share data)Three Months EndedSix Months EndedJun. 30,Jun. 30,Jun. 30,Jun. 30,2013201220132012GAAP net income (loss)$ 12,351$ (16,906)$ (39,560)$ (29,729)Adjustments:Research and Development share-based compensation (2)

3,7601,01314,9403,708General and Administrative share-based compensation (2)

3,10183515,4991,6256,8611,84830,4395,333Non-GAAP net income (loss)$ 19,212$ (15,058)$   (9,121)$ (24,396)GAAP net income (loss) per share - basic$
.17$
(0.24)$
(0
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Calif. , July 29, 2015 Sangamo ... the company will release its second quarter 2015 financial ... 2015. The press release will be followed by a ... open to the public via telephone and webcast. During ... financial results and discuss other business matters. ...
(Date:7/29/2015)... 29, 2015 Alvarado Hospital unveiled its ... Alvarado Spine & Joint Institute. The institute is ... on spinal surgery and joint replacement. The Spine ... a patient experience-focused approach. For example, patients are ... in, rather than patient gowns. ...
(Date:7/29/2015)... July 29, 2015   Turing Pharmaceuticals AG ... joined the company as its first Chief Communication Officer. ... have overall responsibility for internal and external communications and ... He will report directly to Founder and Chairman, ... Leadership Team. "We are excited to have ...
Breaking Medicine Technology:Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 3
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:7/29/2015)... ... 2015 , ... Abt Associates has named Selena Ramkeesoon, a ... In her position, Ramkeesoon will help build and expand work in communications, and ... to a decade at ICF International, most recently as a vice president. During ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the The Media ... and are exposed to advertisements, for medicinal use are more likely to abuse the ... the use of marijuana is considered beneficial are more apt to use the substance, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may ... MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with ...
(Date:7/29/2015)... ... 29, 2015 , ... The NCCA re-accredited the Commission for ... 30, 2019, during its recent meeting. , The Commission received renewal of NCCA ... with the NCCA’s Standards for the Accreditation of Certification Programs. NCCA is ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , The ... , and “reflects the evolution of our training center over the past three ...
Breaking Medicine News(10 mins):Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4
... A new study shows that exposure to a chemical ... be harmful to the nose and airways of mice. ... (NIEHS), part of the National Institutes of Health, conducted ... obliterative bronchiolitis (OB) in humans. OB is a debilitating ...
... A commonly used medication that prevents blood clots ... delicate vein walls and may accelerate healing in ... research from the University of Michigan Cardiovascular Center. ... evidence to support the aggressive anti-clot efforts now under ...
... been shown to reduce the postembolization pain during ... as a complementary approach to pharmacological analgesia according ... issue of the World Journal of Gastroenterology. , ... and after transarterial embolization. Large doses of opioid ...
... volume 14 issue 6 of World Journal of ... Dr Cosimo Sperti of University of Padua, Padova, ... in another hospital for an unresectable pancreatic cystic ... pancreatectomy together with resection and reconstruction of portal ...
... It, Don,t Repeat It: ... WASHINGTON, March 13 More than half of ... negative impact on important relationships -- at work, at ... national survey commissioned by the,Anxiety Disorders Association of America ...
... Christwood Represents LTC Model for the Future, ... Inc., the long-term,care (LTC) industry,s technology partner, ... the company,s second Outcome Based Study,(OBS) partner ... Enterprise Quality Improvement System., Christwood, which ...
Cached Medicine News:Health News:Rodent study finds artificial butter chemical harmful to lungs 2Health News:Damaged veins heal faster with heparin treatment, laboratory study finds 2Health News:Damaged veins heal faster with heparin treatment, laboratory study finds 3Health News:Damaged veins heal faster with heparin treatment, laboratory study finds 4Health News:Psychological intervention reduces postembolization pain 2Health News:Video: New Survey Reveals More Than Half of Adults With OCD Say the Disorder Has a Negative Impact on Relationships at Home, Work and in Their Personal Life 2Health News:Video: New Survey Reveals More Than Half of Adults With OCD Say the Disorder Has a Negative Impact on Relationships at Home, Work and in Their Personal Life 3Health News:Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industry's Only Enterprise Quality Improvement System 2Health News:Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industry's Only Enterprise Quality Improvement System 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: